|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...345678910111213...4041» |
- Trial completion, Enrollment change: Walking With FES or AFO in People With MS With Foot Drop (clinicaltrials.gov) - Apr 4, 2016
P=N/A, N=18, Completed, Sponsor: Queen Margaret University
Recruiting --> Completed | N=24 --> 18
- ZB-168 / Zura Bio
Trial initiation date, Trial primary completion date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Mar 31, 2016
P1, N=60, Terminated, Sponsor: Pfizer
Recruiting --> Completed | N=24 --> 18 Trial primary completion date: Jun 2017 --> Oct 2015 | Initiation date: Jun 2014 --> Sep 2014
- |||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Trial primary completion date: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) - Mar 30, 2016
P4, N=98, Completed, Sponsor: EMD Serono
Trial primary completion date: Jun 2017 --> Oct 2015 | Initiation date: Jun 2014 --> Sep 2014 Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2016
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
P1 data, Trial primary completion date, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 30, 2016
P1, N=12, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- methylphenidate tablet / Generic mfg.
Enrollment closed, Trial primary completion date: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Mar 29, 2016
P2/3, N=24, Active, not recruiting, Sponsor: Oregon Health and Science University
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Apr 2016
- Enrollment closed, Trial initiation date, Trial primary completion date: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Mar 28, 2016
P2, N=60, Active, not recruiting, Sponsor: VA Office of Research and Development
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Apr 2016 Not yet recruiting --> Active, not recruiting | Initiation date: Jul 2015 --> Oct 2015 | Trial primary completion date: Dec 2015 --> May 2016
- Trial completion: Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate (clinicaltrials.gov) - Mar 28, 2016
P=N/A, N=200, Completed, Sponsor: Klinikum Ludwigshafen
Not yet recruiting --> Active, not recruiting | Initiation date: Jul 2015 --> Oct 2015 | Trial primary completion date: Dec 2015 --> May 2016 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial termination, Trial primary completion date: Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) (clinicaltrials.gov) - Mar 28, 2016
P1/2, N=44, Terminated, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Dec 2015; The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial
- fipaxalparant (AMG 670) / Amgen
Trial primary completion date: Proof of Biological Activity of SAR100842 in Systemic Sclerosis (clinicaltrials.gov) - Mar 25, 2016
P2, N=32, Completed, Sponsor: Sanofi
Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Dec 2015; The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial Trial primary completion date: Apr 2014 --> Nov 2013
- ||||||| teriflunomide / Generic mfg.
Trial completion: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Mar 25, 2016
P3, N=618, Completed, Sponsor: Sanofi
Trial primary completion date: Apr 2014 --> Nov 2013 Active, not recruiting --> Completed
- Trial completion: Sclerocadh1: Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis (clinicaltrials.gov) - Mar 24, 2016
P=N/A, N=85, Completed, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed Recruiting --> Completed
- | Vitaros (alprostadil + novel excipient) / Seelos Therap
Trial completion: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Mar 22, 2016
P2, N=35, Completed, Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Recruiting --> Completed Active, not recruiting --> Completed
- Myrbetriq (mirabegron) / Astellas
Trial primary completion date: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - Mar 19, 2016
P2/3, N=144, Enrolling by invitation, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- || Betaseron (IFN-β-1b) / Bayer
Enrollment change, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Mar 17, 2016
P=N/A, N=138, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jun 2016 --> Jun 2017 N=300 --> 138
- | Cosentyx (secukinumab) / Novartis
Trial completion: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Mar 15, 2016
P2, N=39, Completed, Sponsor: Novartis Pharmaceuticals
N=300 --> 138 Active, not recruiting --> Completed
- ||||||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (clinicaltrials.gov) - Mar 15, 2016
P3, N=1322, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Mar 11, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Enrollment closed: Study of Electrical Impedance Myography (EIM) in ALS (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Skulpt, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: An In-home Study of Brain Computer Interfaces (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=1, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | Trial primary completion date: Aug 2015 --> May 2011
- Trial completion: Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS (clinicaltrials.gov) - Mar 5, 2016
P3, N=32, Completed, Sponsor: Lawson Health Research Institute
Enrolling by invitation --> Completed | Trial primary completion date: Aug 2015 --> May 2011 Recruiting --> Completed
- | Biomarker, Trial completion, Enrollment change, Trial primary completion date: A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=20, Completed, Sponsor: Sanguine Biosciences
Recruiting --> Completed Recruiting --> Completed | N=600 --> 20 | Trial primary completion date: Oct 2015 --> Mar 2015
- | Trial completion, Trial initiation date, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Mar 5, 2016
P4, N=42, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=600 --> 20 | Trial primary completion date: Oct 2015 --> Mar 2015 Recruiting --> Completed | Initiation date: Jul 2012 --> Oct 2012
- C-82 Topical Gel, 1% / PRISM Pharma
Biomarker, Trial primary completion date: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial (clinicaltrials.gov) - Mar 4, 2016
P1/2, N=18, Recruiting, Sponsor: Prism Pharma Co., Ltd.
Recruiting --> Completed | Initiation date: Jul 2012 --> Oct 2012 Trial primary completion date: Jan 2016 --> Apr 2016
- Biomarker, Trial primary completion date: Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=30, Recruiting, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Dec 2015 --> May 2016
- GZ402668 / Sanofi
Enrollment closed: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 4, 2016
P1, N=44, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=144, Active, not recruiting, Sponsor: Niguarda Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- |||| mecobalamin (E0302) / Eisai
Trial primary completion date: A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 1, 2016
P2/3, N=300, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Feb 2016 --> Mar 2017
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: OLYMPUS: A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 27, 2016
P2/3, N=439, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Feb 2016 --> Mar 2017 Active, not recruiting --> Completed
- | Trial completion: Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis (clinicaltrials.gov) - Feb 27, 2016
P3, N=76, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Avonex (recombinant IFN-?-1a) / Biogen
Trial completion, Combination therapy: Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis (clinicaltrials.gov) - Feb 27, 2016
P4, N=16, Completed, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis (clinicaltrials.gov) - Feb 24, 2016
P2, N=13, Completed, Sponsor: University of Jordan
No longer recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Oct 2015 --> Feb 2016
- Trial completion: Evaluating Intervention Responsiveness in People With Multiple Sclerosis (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=60, Completed, Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed
- Enrollment closed, Enrollment change: T and B Cell Responses in Autoimmune Diseases (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=68, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=280 --> 68
- Trial completion, Enrollment change, Trial primary completion date: Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients (clinicaltrials.gov) - Feb 22, 2016
P=N/A, N=42, Completed, Sponsor: Hospital Universitari de Bellvitge
Recruiting --> Active, not recruiting | N=280 --> 68 Recruiting --> Completed | N=72 --> 42 | Trial primary completion date: Apr 2015 --> Dec 2015
- Enrollment closed, HEOR: ermoSla: Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Feb 22, 2016
P=N/A, N=67, Active, not recruiting, Sponsor: Azienda Unita' Sanitaria Locale Di Modena
Recruiting --> Completed | N=72 --> 42 | Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- ||||||| Trial completion: OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 18, 2016
P3, N=579, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- teriflunomide / Generic mfg.
Trial completion, Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Feb 13, 2016
P=N/A, N=50, Completed, Sponsor: University at Buffalo
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015
- Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study (clinicaltrials.gov) - Feb 13, 2016
P=N/A, N=159, Completed, Sponsor: University at Buffalo
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015 Active, not recruiting --> Completed
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P4, N=218, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Apr 2016
- Enrollment closed: Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: University at Buffalo
Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- Trial completion: Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=499, Completed, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- || Copaxone 3TW (glatiramer acetate three times a week) / Teva
Trial primary completion date: Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=150, Enrolling by invitation, Sponsor: University at Buffalo
Enrolling by invitation --> Completed Trial primary completion date: Jul 2015 --> Apr 2016
- | Trial completion: Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 11, 2016
P2/3, N=56, Completed, Sponsor: VA Office of Research and Development
Trial primary completion date: Jul 2015 --> Apr 2016 Active, not recruiting --> Completed
- Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Feb 11, 2016
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jan 2017
- ||| Trial completion: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=65, Completed, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed
- Enrollment open, Trial initiation date, Trial primary completion date: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=35, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2015 | Trial primary completion date: Feb 2016 --> Nov 2016
- Preclinical, Trial primary completion date: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2016
P2, N=50, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2015 | Trial primary completion date: Feb 2016 --> Nov 2016 Trial primary completion date: Nov 2012 --> Mar 2013
- Trial initiation date, Trial primary completion date: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 3, 2016
P2, N=30, Not yet recruiting, Sponsor: University Hospital of Ferrara
Trial primary completion date: Nov 2012 --> Mar 2013 Initiation date: Apr 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion: Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=40, Completed, Sponsor: University Hospital of Ferrara
Initiation date: Apr 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed
- ||||||| dalfampridine / Generic mfg.
Trial completion: Study of Oral Fampridine-SR in Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2016
P3, N=301, Completed, Sponsor: Acorda Therapeutics
Recruiting --> Completed No longer recruiting --> Completed